You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 6,344,213


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,344,213
Title: Compounds and compositions for delivering active agents
Abstract:Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
Inventor(s): Leone-Bay; Andrea (Ridgefield, CT), Milstein; Sam J. (Larchmont, NY), Sarrubi; Donald J. (Bronxville, NY), Leipold; Harry (Elmsford, NY)
Assignee: Emisphere Technologies, Inc. (Tarrytown, NY)
Application Number:08/820,694
Patent Claims:1. A pharmacological composition comprising:

(A) at least one biologically-active agent selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytosin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, an antimicrobial, an antifungal agent, and combinations thereof; and

(B) at least one carrier compound having the formula:

wherein Ar is an unsubstituted phenyl or naphthyl;

R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alky, C.sub.4 to C.sub.20 alkenyl, phenyl, naphthyl, (C.sub.1 to C.sub.10 alkenyl)phenyl, (C.sub.1 to C.sub.10 alkyl)naphthyl, (C.sub.1 to C.sub.10 alkenyl)naphthyl, phenyl (C.sub.1 to C.sub.10 alkenyl), naphthyl (C.sub.1 to C.sub.10 alkyl), and naphthyl (C.sub.1 to C.sub.10 alkenyl);

R.sup.8 is selected from the group consisting of hydrogen, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, hydroxy, and C.sub.1 to C.sub.4 alkoxy;

R.sup.7 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH and --CO.sub.2 R.sup.9 or any combination thereof;

R.sup.9 is hydrogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkenyl;

R.sup.7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group;

or salts thereof.

2. The composition according to claim 1, wherein said biologically-active agent comprises calcitonin.

3. The composition according to claim 1, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl and C.sub.4 to C.sub.20 alkenyl.

4. The composition according to claim 1, wherein R.sup.7 is selected from the group consisting of C.sub.5 to C.sub.20 alkyl and C.sub.5 to C.sub.20 alkenyl.

5. The composition according to claim 1 wherein the carrier has the formula: ##STR67##

or salts thereof.

6. A dosage unit form comprising:

(A) a pharmacological composition according to claim 3; and

(B)

(a) an excipient,

(b) a diluent,

(c) a disintegrant,

(d) a lubricant,

(e) a plasticizer,

(f) a colorant,

(g) a dosing vehicle, or

(h) any combination thereof.

7. A dosage unit form according to claim 6, comprising a tablet, a capsule, or a liquid.

8. A dosage unit form according to claim 7, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol or any combination thereof.

9. A method for administering a biologically-active agent to a mammal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 3.

10. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 3.

11. The composition according to claim 3, wherein said biologically-active agent comprises human growth hormone.

12. The composition according to claim 3, wherein said biologically-active agent comprises heparin.

13. The composition according to claim 3, wherein said biologically-active agent comprises low molecular weight heparin.

14. The composition according to claim 3, wherein said biologically-active agent comprises parathyroid hormone.

15. The composition according to claim 3, wherein said biologically-active agent comprises insulin.

16. A pharmacological composition comprising:

(A) at least one biologically active agent;

(B) at least one carrier compound having the formula:

or salts thereof,

wherein Ar is unsubstituted phenyl

R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, phenyl, naphthyl, (C.sub.1 to C.sub.10 alkenyl)phenyl, (C.sub.1 to C.sub.10 alkyl)naphthyl, (C.sub.1 to C.sub.10 alkenyl)naphthyl, phenyl(C.sub.1 to C.sub.10 alkenyl), naphthyl(C.sub.1 to C.sub.10 alkyl), naphthyl(C.sub.1 to C.sub.10 alkenyl);

R.sup.8 is hydrogen;

R.sup.7 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH and --CO.sub.2 R.sup.9 or any combination thereof;

R.sup.9 is hydrogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkenyl;

R.sup.7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group.

17. The composition according to claim 16, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl and C.sub.4 to C.sub.20 alkenyl.

18. The composition according to claim 17, wherein R.sup.7 is selected from the group consisting of C.sub.5 to C.sub.20 alkyl and C.sub.5 to C.sub.20 alkenyl.

19. The composition according to claim 17, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytosin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, an antimicrobial, an antifungal agent, or a combination thereof.

20. The composition according to claim 19, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, desferrioxamine and combinations thereof.

21. The composition according to claim 20, wherein said biologically-active agent comprises calcitonin.

22. The composition according to claim 20, wherein said biologically-active agent comprises human growth hormone.

23. The composition according to claim 20, wherein said biologically-active agent comprises heparin.

24. The composition according to claim 20, wherein said biologically-active agent comprises low molecular weight heparin.

25. The composition according to claim 20, wherein said biologically-active agent comprises insulin.

26. A dosage unit form comprising:

(A) a pharmacological composition according to claim 17; and

(B)

(i) an excipient,

(ii) a diluent,

(iii) a disintegrant,

(iv) a lubricant,

(v) a plasticizer,

(vi) a colorant,

(vii) a dosing vehicle, or

(viii) any combination thereof.

27. A dosage unit form according to claim 26, comprising a tablet, a capsule, or a liquid.

28. A dosage unit form according to claim 26, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol or any combination thereof.

29. A method for administering a biologically-active agent to a mammal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 17.

30. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 17.

31. The composition according to claim 16, wherein said carrier has the formula: ##STR68##

or a salt thereof, and said biologically active agent is heparin.

32. The composition according to claim 16, wherein said carrier has the formula: ##STR69##

or a salt thereof, and said biologically active agent is low molecular weight heparin.

33. The composition according to claim 16, wherein said carrier has the formula: ##STR70##

or a salt thereof, and said biologically active agent is heparin.

34. The composition according to claim 16, wherein said carrier has the formula: ##STR71##

or a salt thereof, and said biologically active agent is low molecular weight heparin.

35. The composition according to claim 3, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, desferrioxamine or a combination thereof.

36. A pharmacological composition comprising:

(A) parathyroid hormone; and

(B) at least one carrier compound having the formula:

wherein Ar is an unsubstituted phenyl or naphthyl;

R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, phenyl, naphthyl, (C.sub.1 to C.sub.10 alkenyl)phenyl, (C.sub.1 to C.sub.10 alkyl)naphthyl, (C.sub.1 to C.sub.10 alkenyl)naphthyl, phenyl (C.sub.1 to C.sub.10 alkenyl), naphthyl (C.sub.1 to C.sub.10 alkyl), and naphthyl (C.sub.1 to C.sub.10 alkenyl);

R.sup.8 is selected from the group consisting of hydrogen, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, hydroxy, and C.sub.1 to C.sub.4 alkoxy;

R.sup.7 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH and --CO.sub.2 R.sup.9 or any combination thereof;

R.sup.9 is hydrogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkenyl;

R.sup.7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group; or salts thereof.

37. The composition according to claim 36, wherein R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl and C.sub.4 to C.sub.20 alkenyl.

38. The composition according to claim 36, wherein R.sup.7 is selected from the group consisting of C.sub.5 to C.sub.20 alkyl and C.sub.5 to C.sub.20 alkenyl.

39. The composition according to claim 36, wherein the carrier has the formula: ##STR72##

or salts thereof.

40. A dosage unit form comprising:

(A) a pharmacological composition according to claim 37; and

(B)

(i) an excipient,

(ii) a diluent,

(iii) a disintegrant,

(iv) a lubricant,

(v) a plasticizer,

(vi) a colorant,

(vii) a dosing vehicle, or

(viii) any combination thereof.

41. A dosage unit form according to claim 40, comprising a tablet, a capsule, or a liquid.

42. A dosage unit form according to claim 40, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol or any combination thereof.

43. A method for administering parathyroid hormone to a animal in need thereof, said method comprising administering orally to said animal a composition as defined in claim 37.

44. A pharmacological composition comprising:

(A) at least one biologically active agent selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytosin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, an antimicrobial, an antifungal agent, and combinations thereof; and

(B) at least one carrier compound having the formula:

or salts thereof,

wherein Ar is unsubstituted phenyl;

R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, phenyl, naphthyl, (C.sub.1 to C.sub.10 alkenyl)phenyl, (C.sub.1 to C.sub.10 alkyl)naphthyl, (C.sub.1 to C.sub.10 alkenyl)naphthyl, phenyl(C.sub.1 to C.sub.10 alkenyl), naphthyl(C.sub.1 to C.sub.10 alkyl), naphthyl(C.sub.1 to C.sub.10 alkenyl);

R.sup.8 is hydrogen;

R.sup.7 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH and --CO.sub.2 R.sup.9 or any combination thereof;

R.sup.9 is hydrogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkenyl;

R.sup.7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group.

45. A pharmacological composition comprising:

(A) parathyroid hormone; and

(B) at least one carrier compound having the formula:

or salts thereof,

wherein Ar is unsubstituted phenyl;

R.sup.7 is selected from the group consisting of C.sub.4 to C.sub.20 alkyl, C.sub.4 to C.sub.20 alkenyl, phenyl, naphthyl, (C.sub.1 to C.sub.10 alkenyl)phenyl, (C.sub.1 to C.sub.10 alkyl)naphthyl, (C.sub.1 to C.sub.10 alkenyl)naphthyl, phenyl(C.sub.1 to C.sub.10 alkenyl), naphthyl(C.sub.1 to C.sub.10 alkyl), naphthyl(C.sub.1 to C.sub.10 alkenyl);

R.sup.8 is hydrogen;

R.sup.7 is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkenyl, C.sub.1 to C.sub.4 alkoxy, --OH, --SH and --CO.sub.2 R.sup.9 or any combination thereof;

R.sup.9 is hydrogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkenyl;

R.sup.7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group.

46. A dosage unit form comprising:

(A) a pharmacological composition according to claim 1; and

(B)

(a) an excipient,

(b) a diluent,

(c) a disintegrant,

(d) a lubricant,

(e) a plasticizer,

(f) a colorant,

(g) a dosing vehicle, or

(h) any combination thereof.

47. A dosage unit form comprising:

(A) a pharmacological composition according to claim 4; and

(B)

(a) an excipient,

(b) a diluent,

(c) a disintegrant,

(d) a lubricant,

(e) a plasticizer,

(f) a colorant,

(g) a dosing vehicle, or

(h) any combination thereof.

48. A dosage unit form comprising:

(A) a pharmacological composition according to claim 5; and

(B)

(a) an excipient,

(b) a diluent,

(c) a disintegrant,

(d) a lubricant,

(e) a plasticizer,

(f) a colorant,

(g) a dosing vehicle, or

(h) any combination thereof.

49. A method for preparing a pharmacological composition, said method comprising mixing:

(A) at least one biologically-active agent;

(B) at least one carrier compound according to claim 3, and

(C) optionally a dosing vehicle.

50. A method for preparing a pharmacological composition, said method comprising mixing:

(A) at least one biologically-active agent;

(B) at least one carrier compound according to claim 4; and

(C) optionally a dosing vehicle.

51. A method for preparing a pharmacological composition, said method comprising mixing:

(A) at least one biologically-active agent;

(B) at least one carrier compound according to claim 5; and

(C) optionally a dosing vehicle.

52. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 1.

53. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 4.

54. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 5.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - HIPAA-ready chat for life sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group